KR20020015906A - 잎새버섯 추출물을 포함하는 화학요법 항암제시스플라틴의 부작용 억제제 - Google Patents
잎새버섯 추출물을 포함하는 화학요법 항암제시스플라틴의 부작용 억제제 Download PDFInfo
- Publication number
- KR20020015906A KR20020015906A KR1020000049043A KR20000049043A KR20020015906A KR 20020015906 A KR20020015906 A KR 20020015906A KR 1020000049043 A KR1020000049043 A KR 1020000049043A KR 20000049043 A KR20000049043 A KR 20000049043A KR 20020015906 A KR20020015906 A KR 20020015906A
- Authority
- KR
- South Korea
- Prior art keywords
- cisplatin
- group
- side effects
- cancer
- side effect
- Prior art date
Links
- 229960004316 cisplatin Drugs 0.000 title claims abstract description 71
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 title claims abstract description 71
- 230000000694 effects Effects 0.000 title claims abstract description 27
- 239000000284 extract Substances 0.000 title claims abstract description 16
- 240000001080 Grifola frondosa Species 0.000 title abstract description 4
- 235000007710 Grifola frondosa Nutrition 0.000 title abstract description 4
- 239000003112 inhibitor Substances 0.000 claims abstract description 8
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 19
- 241000411851 herbal medicine Species 0.000 claims description 3
- 239000009536 samultang Substances 0.000 claims description 2
- 102000000588 Interleukin-2 Human genes 0.000 abstract description 14
- 108010002350 Interleukin-2 Proteins 0.000 abstract description 14
- 206010028980 Neoplasm Diseases 0.000 abstract description 14
- 201000011510 cancer Diseases 0.000 abstract description 12
- 238000002512 chemotherapy Methods 0.000 abstract description 9
- 231100000419 toxicity Toxicity 0.000 abstract description 9
- 230000001988 toxicity Effects 0.000 abstract description 9
- 230000007423 decrease Effects 0.000 abstract description 7
- 239000002246 antineoplastic agent Substances 0.000 abstract description 6
- 229940044683 chemotherapy drug Drugs 0.000 abstract description 3
- 210000003734 kidney Anatomy 0.000 abstract description 2
- 210000004798 organs belonging to the digestive system Anatomy 0.000 abstract 1
- 210000001772 blood platelet Anatomy 0.000 description 10
- 210000000952 spleen Anatomy 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 230000002496 gastric effect Effects 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 230000003394 haemopoietic effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000001079 digestive effect Effects 0.000 description 5
- 231100000417 nephrotoxicity Toxicity 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000012829 chemotherapy agent Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 2
- 239000011121 hardwood Substances 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 231100000386 immunotoxicity Toxicity 0.000 description 2
- 230000007688 immunotoxicity Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 240000000731 Fagus sylvatica Species 0.000 description 1
- 235000010099 Fagus sylvatica Nutrition 0.000 description 1
- 241000222684 Grifola Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241000219492 Quercus Species 0.000 description 1
- 235000016976 Quercus macrolepis Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000032383 Soft tissue cancer Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000001909 effect on DNA Effects 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002766 immunoenhancing effect Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000000738 kidney tubule Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
실험군 | 대조군 | 시스플라틴 | 시스플라틴 +0.5 g/Kg | 시스플라틴 +1.0 g/Kg |
혈소판 (103/mm3) | 115.3 ± 18.0a) | 31.7 ± 19.9 | 79.1 ± 28.2 | 75.2 ± 15.6 |
실험군 | 대조군 | 시스플라틴 | 시스플라틴 +0.5 g/Kg | 시스플라틴 +1.0 g/Kg |
BUN (mg/dL) | 23.3 ± 4.9a) | 193.8 ± 38.1 | 154.4 ± 57.8 | 120.0 ± 21.9 |
실험군 | 대조군 | 시스플라틴 | 시스플라틴 +0.5 g/Kg | 시스플라틴 +1.0 g/Kg |
위장 (g) | 0.481 ± 0.063a) | 0.663 ± 0.092 | 0.483 ± 0.075 | 0.491 ± 0.102 |
Claims (3)
- 잎새버섯의 추출물을 함유하는 것을 특징으로 하는 시스플라틴 부작용 억제제
- 제 1 항에 있어서, 상기부작용 억제제에는 한약재 및 한방처방이 더 부가되는 것을 특징으로 하는 시스플라틴 부작용 억제제
- 제 1 항에 있어서, 상기 한방 처방은 사물탕인 것을 특징으로 하는 시스플라틴 부작용 억제제
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2000-0049043A KR100501039B1 (ko) | 2000-08-23 | 2000-08-23 | 잎새버섯 추출물을 포함하는 화학요법 항암제시스플라틴의 부작용 억제제 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2000-0049043A KR100501039B1 (ko) | 2000-08-23 | 2000-08-23 | 잎새버섯 추출물을 포함하는 화학요법 항암제시스플라틴의 부작용 억제제 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20020015906A true KR20020015906A (ko) | 2002-03-02 |
KR100501039B1 KR100501039B1 (ko) | 2005-07-18 |
Family
ID=19684785
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2000-0049043A KR100501039B1 (ko) | 2000-08-23 | 2000-08-23 | 잎새버섯 추출물을 포함하는 화학요법 항암제시스플라틴의 부작용 억제제 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100501039B1 (ko) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014073855A1 (ko) * | 2012-11-08 | 2014-05-15 | 한국한의학연구원 | 천연물 추출물 또는 이의 분획물을 유효성분으로 포함하는 급성신부전의 예방 또는 치료용 조성물 |
KR20160059177A (ko) * | 2014-11-18 | 2016-05-26 | 한국 한의학 연구원 | 가시여뀌 추출물을 유효성분으로 함유하는 항암제 유도 조혈 독성의 예방 및 치료용 약학적 조성물 및 건강기능식품 |
KR20180078435A (ko) | 2016-12-29 | 2018-07-10 | 경희대학교 산학협력단 | 식욕부진 개선용 건강기능식품 조성물 및 식욕부진 예방 또는 치료용 약학 조성물 |
KR102143937B1 (ko) | 2020-04-02 | 2020-08-12 | (주)송헌알앤디 | 혼합 생약 추출물을 유효성분으로 포함하는 항암제 부작용의 완화, 개선 또는 치료용 조성물 |
KR102185919B1 (ko) | 2020-04-02 | 2020-12-03 | (주)송헌알앤디 | 혼합 생약 추출물을 유효성분으로 포함하는 항암제 부작용의 완화, 개선 또는 치료용 조성물 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101684574B1 (ko) | 2014-11-18 | 2016-12-08 | 한국 한의학 연구원 | 구척 추출물을 유효성분으로 함유하는 항암제 유도 조혈 독성의 예방 및 치료용 약학적 조성물 및 건강기능식품 |
KR101985965B1 (ko) | 2018-01-03 | 2019-09-03 | 원광대학교산학협력단 | 복합 생약 추출물을 유효성분으로 함유하는, 시스플라틴에 의한 부작용 예방, 개선 또는 치료용 약학적 조성물 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62207224A (ja) * | 1986-03-08 | 1987-09-11 | Nippon Haipotsukusu:Kk | 抗種瘍剤の副作用軽減剤 |
JPH01207242A (ja) * | 1988-02-15 | 1989-08-21 | Tsumura & Co | 副作用軽減剤 |
JPH06321792A (ja) * | 1993-05-18 | 1994-11-22 | Tsumura & Co | 副作用軽減剤 |
JP2859843B2 (ja) * | 1996-03-08 | 1999-02-24 | 株式会社雪国まいたけ | マイタケから抽出した抗腫瘍物質 |
KR19990029838A (ko) * | 1997-09-19 | 1999-04-26 | 테츠로 이케카와 | 버섯 또는 그 추출물을 함유하는 조성물 |
-
2000
- 2000-08-23 KR KR10-2000-0049043A patent/KR100501039B1/ko active IP Right Grant
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014073855A1 (ko) * | 2012-11-08 | 2014-05-15 | 한국한의학연구원 | 천연물 추출물 또는 이의 분획물을 유효성분으로 포함하는 급성신부전의 예방 또는 치료용 조성물 |
US9737583B2 (en) | 2012-11-08 | 2017-08-22 | Korea Institute Of Oriental Medicine | Composition for prevention or treatment of acute renal failure including herbal extract or fraction thereof as active ingredient |
KR20160059177A (ko) * | 2014-11-18 | 2016-05-26 | 한국 한의학 연구원 | 가시여뀌 추출물을 유효성분으로 함유하는 항암제 유도 조혈 독성의 예방 및 치료용 약학적 조성물 및 건강기능식품 |
KR20180078435A (ko) | 2016-12-29 | 2018-07-10 | 경희대학교 산학협력단 | 식욕부진 개선용 건강기능식품 조성물 및 식욕부진 예방 또는 치료용 약학 조성물 |
KR102143937B1 (ko) | 2020-04-02 | 2020-08-12 | (주)송헌알앤디 | 혼합 생약 추출물을 유효성분으로 포함하는 항암제 부작용의 완화, 개선 또는 치료용 조성물 |
KR102185919B1 (ko) | 2020-04-02 | 2020-12-03 | (주)송헌알앤디 | 혼합 생약 추출물을 유효성분으로 포함하는 항암제 부작용의 완화, 개선 또는 치료용 조성물 |
Also Published As
Publication number | Publication date |
---|---|
KR100501039B1 (ko) | 2005-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Harhaji et al. | Anti-tumor effect of Coriolus versicolor methanol extract against mouse B16 melanoma cells: in vitro and in vivo study | |
CN101559084B (zh) | 一种抗肿瘤的药物组合物及其生产方法 | |
KR100501039B1 (ko) | 잎새버섯 추출물을 포함하는 화학요법 항암제시스플라틴의 부작용 억제제 | |
US10842774B2 (en) | Inhibited expression of PD-L1 and enhanced expression of PD-1 | |
CN113694085A (zh) | 蛞蝓提取物在制备癌症化疗方案的联用药物中的应用 | |
KR100675269B1 (ko) | 오미자 및/또는 산머루 추출물을 함유한 항암 치료의부작용 완화제 | |
CN101904892B (zh) | 苏木提取物制备灌注液制备工艺及其在治疗膀胱癌上的用途 | |
KR100814351B1 (ko) | 담자균류 및 두릅나무과 추출물의 생리학적 활성 조성물 | |
US6537587B1 (en) | Compositions containing muscle-derived active agents | |
EP0796620B1 (en) | An anti-viral and anti-cancer agent from "Aspalathus Linearis" | |
KR101151701B1 (ko) | 허수타노놀을 유효성분으로 포함하는 아토피성 피부염 개선용 조성물 | |
US8003137B2 (en) | Extracts of Aristolochia paucinervis pomel and uses thereof | |
EP4248964A1 (en) | Pharmaceutical composition for treating sepsis, and use thereof | |
US20180064774A1 (en) | Compositions for use in the treatment of tumors resistant to chemotherapy | |
KR20010111569A (ko) | 전선화(야생 메꽃)의 고분자량 추출물 | |
CN114177180A (zh) | 依鲁替尼的药物组合物 | |
KR20080101344A (ko) | 탄닌 함유 해동피 추출물을 유효성분으로 하는 소염 진통제조성물 | |
CN1919191A (zh) | 环淫羊藿甙元作为制备防治器官移植排斥反应药物的应用 | |
Kellner et al. | Biological Effect of 1: 6-Dimethane-Sulphony-D-Mannitol in Animal Experiments | |
CN113181173B (zh) | 药用组合物及其在制备用于预防和/或治疗肝癌的产品中的应用 | |
US8404287B2 (en) | Use of Fructus schisandrae and extracts thereof in preventing and decreasing toxic and side effects of antineoplastic drugs | |
CN112156117B (zh) | 垂枝藓醇提物及其制备方法和垂枝藓醇提物在制备抗肝癌药物中的应用 | |
CN100515461C (zh) | 藤黄软膏制剂 | |
KR100470976B1 (ko) | 간염 치료제 및 예방제 또는 간보호제로 유용한 오갈피추출물 | |
WO2009136898A2 (en) | Extracts of aristolochia longa pomer and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20030821 Effective date: 20050328 |
|
S901 | Examination by remand of revocation | ||
GRNO | Decision to grant (after opposition) | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130627 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20140418 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20160704 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20170822 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20180704 Year of fee payment: 14 |